Raltegravir (RAL), the first-licensed compound of the integrase inhibitor (INI) drug class, is active against HIV type 2 (HIV-2), since the phenotypic susceptibility to RAL of wildtype HIV-2 clinical isolates was found in a range similar to that for HIV-1 (12) . Previous studies have established HIV-1 integrase (IN) mutations involved in RAL resistance, which are reported in the different genotypic interpretation algorithms (http://www.hivfrenchresistance.org; http://hivdb.stanford.edu) with primary (Y143H/R/C, Q148K/R/H, N155H) and secondary resistance-associated mutations. Preliminary results for HIV-2 showed that RAL resistance involved the two main resistance mutations, Q148K/R/H and N155H, already described in HIV-1 RAL resistance, with an increase in 50% inhibitory concentration (IC 50 ) for both RAL and elvitegravir (5, 11, 13) .
The aim of the study was to determine genetic mutational pathways associated with the development of resistance to RAL in HIV-2-infected patients.
Seven heavily pretreated HIV-2-infected patients receiving a salvage RAL-containing regimen exhibited incomplete viral suppression or virological failure, defined as plasma HIV-2 RNA level of Ͼ100 copies/ml 3 months after initiation of regimen. HIV-2 viral load quantification was determined by an in-house assay (2) . All of the patients were identified from the French HIV-2 Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) cohort CO5. The median duration of the RAL-based regimen was 14 months (interquartile range [IQR], 12 to 16). The complete IN gene was retrospectively amplified by population-based sequencing from plasma samples collected at baseline and at time of virological failure of RAL-containing treatment, as previously described (12) . RAL resistance-associated mutations were identified among the following: H51Y, T66I/A/K, V72I, L74I/A/M, E92Q, T97A, T112I, F121Y, T125K, A128T, E138K/A/D, G140A/S/R/C/H, Y143C/H/R, Q146K/P, S147G, Q148K/R/H, V151I, S153Y/A, M154I, N155S/H, K156N, E157Q, K160D/N, G163R/K, V165I, V201I, I203M, T206S, S230N/R, V249I, R263K, and C280Y (7). HIV-2 protease and reverse transcriptase sequencing was performed using previously described procedures (4, 10) . Then, mutations known to be involved in HIV-1 and/or HIV-2 resistance were interpreted using the French algorithm (www .hivfrenchresistance.org).
At baseline, the median HIV-2 viral load and CD4 cell count were 4.28 log 10 copies/ml (IQR, 4.00 to 4.50) and 48 cells/mm 3 (IQR, 37 to 109), respectively. Four patients were infected with HIV-2 subtype A, two with subtype B, and one with subtype H. The optimized background therapy associated with RAL for each patient is described in Table 1 . All patients received darunavir boosted with ritonavir. The nucleoside reverse transcriptase inhibitors (NRTI) lamivudine (or emtricitabine), abacavir, tenofovir, and zidovudine were received by six, three, four, and one patient, respectively. Baseline plasma virus exhibited a median number of eight mutations described as associated with resistance in HIV-1 infection ( Table 1 ). The median number of NRTI resistance-associated mutations was 3, with the individual numbers as follows: N69D/S (n ϭ 4), K65R (n ϭ 3), Q151M (n ϭ 3), M184V (n ϭ 3), A62V (n ϭ 2), Y115F (n ϭ 2), D67N (n ϭ 1), K70R (n ϭ 1), S215W (n ϭ 1). The median number of protease inhibitor resistance-associated mutations exhibited by baseline virus was 4, with the individual numbers as follows: V71I (n ϭ 5), I54L/M (n ϭ 4), I50V (n ϭ 3), L90M (n ϭ 3), V33I (n ϭ 2), I82F (n ϭ 2), V20I (n ϭ 1), I46V (n ϭ 1), I84V (n ϭ 1), I89V (n ϭ 1). No RAL resistance-associated mutations were found at baseline by bulk sequencing.
Although baseline viral loads were initially high, especially for HIV-2-infected patients, five of seven patients showed a rapid and remarkable decrease in HIV-2 RNA titers. Indeed, within 3 months after initiation of RAL-containing regimen, the HIV-2 viral load was below the limit of detection (100 copies/ml) in five patients. For the two remaining patients, decreases of 0.26 and 1.00 log 10 copies/ml in HIV-2 level were observed, failing to reach an undetectable level.
A virological rebound was observed at a median of 8 months after RAL treatment initiation among the five patients who initially reached HIV-2 RNA undetectable levels. At the time of virological failure, three different genotypic patterns in the IN gene were observed. Population-based sequencing technology prevented the determination of whether drug resistance mutations are present on the same viral genome.
First, the residue 148 pathway was observed in virus from three patients, with the presence of the Q148R, Q148K, and G140S-Q148R mutations in patients 1, 2, and 4, respectively ( Table 2) . The mutation Q148H, the most frequent mutation detected in HIV-1, was not detected in this series of HIV-2-infected patients. IN genotypic evolution was observed at further time points under continued RAL drug pressure in virus from two patients (1 and 2) , showing the addition of the secondary mutation G140S in one case and the switch from Q148K to the Q148R mutation followed by the addition of the G140S mutation in the second case. Second, for the residue 155 pathway, the N155H mutation was present with the T97A mutation in virus from patient 6. This genetic resistance profile remained stable during the follow-up. Finally, we observed the residue 143 pathway, with the selection of the T97A and Y143C mutations, in virus from two patients (3 and 7). A genotypic evolution was observed, with a switch to the Y143G mutation, in patient 3. Plasma virus from the remaining patient, patient 5, exhibited RAL mutations linked to two distinct genetic pathways, N155H and Y143H/R with the E92Q mutation. IN direct sequencing at further time points showed the disappearance of the Y143H/R mutation and a mixture at residue 92 (E92A/E/P/Q) with the N155H mutation.
The kinetics of development of resistance did not seem to be related to a specific genotypic resistance profile. Of note, the N155H pathway was observed only in the two patients infected with HIV-2 subtype B virus.
The selection of resistance mutations in protease and reverse transcriptase, concomitantly with RAL resistance development, was assessed in the four patients for whom successful genotypic resistance tests were obtained. Compared to the baseline genotype, additional mutations in protease and reverse transcriptase were observed in three patients (patients 2, 3, and 5) at the time of virological failure. The selection of the I15V mutation in protease was observed in virus from two patients (patients 2 and 5), both receiving darunavir boosted with ritonavir. In virus from patient 3, I89V and L90M mutations emerged in protease and the A62V mutation disappeared in reverse transcriptase at the time of virological failure.
This study showed, among seven highly antiretrovirus-experienced HIV-2-infected patients displaying virological failure while receiving a RAL-containing regimen, the role in the development of HIV-2 resistance to INIs of the three main resistance pathways: Q148H/K/R, N155H, and Y143C/H/R. This study pointed out the genetic profiles of HIV-2 resistance to RAL. Despite an approximately 40% amino acid difference between HIV-2 and HIV-1 in wild-type IN genes, these profiles seemed to be quite similar to those found in HIV-1 infection (1), involving similar residues at the same key positions in the development of resistance among HIV-1 and HIV-2 infections. One explanation could be the 100% conser- 143  3  T97A-Y143C  T97A-Y143G  7  T97A-Y143C  T97A-Y143C   148  1  Q148R  G140S-Q148R  2  Q148K  G140S-Q148R  4 G140S-Q148R G140S-Q148R
vation of the catalytic triad DDE and the HHCC and RKK motifs between HIV-1 and HIV-2 (7). Genotypic evolution of RAL resistance profiles was observed over time in patients who remained on a failing RALcontaining regimen, mainly corresponding to the selection of secondary RAL resistance-associated mutations, known to improve the viral replicative capacity (6) . In HIV-2-infected patients assessed in our study, no switch of genotypic resistance profile from residue 155 to 148 or from residue 155 to 143 was evidenced, conversely to what was observed in different HIV-1 RAL resistance studies (3, 8, 9) . Studies assessing HIV-2 viral replicative capacity and phenotypic resistance level are needed to better describe the impact of RAL resistance-associated mutations in this genetic context.
Nucleotide sequence accession numbers. Integrase sequences were submitted to GenBank and given the following accession numbers: HQ694834 to HQ694845.
